Pharmacy giant Walgreens has agreed to pay $2.8 million to settle allegations that it inflated generic drug prices submitted to Medicaid programs in Massachusetts and Georgia—a case that stemmed from whistleblower claims and a federal False Claims Act lawsuit.

Federal prosecutors announced the agreement Thursday, marking yet another legal challenge for the retail drugstore chain, which has faced increased scrutiny over pharmaceutical pricing practices and compliance issues.

Allegations of Inflated Medicaid Prices

The controversy revolves around how Walgreens reported drug prices to Medicaid. State reimbursement programs determine payments based on the lowest available pricing, including a pharmacy’s “usual and customary price”—the amount the store regularly charges customers.

According to federal prosecutors, between 2008 and 2023, Walgreens submitted artificially high pricing for certain generic drugs, leading to inflated reimbursements from Medicaid programs in Massachusetts and Georgia.

Despite the settlement, Walgreens declined to comment on the case.

Whistleblowers Uncover Deceptive Practices

The lawsuit was fueled by whistleblower complaints from Donna Chambers and Irene Gendel, both longtime Walgreens employees. Chambers, a pharmacy manager, and Gendel, a staff pharmacist, detailed multiple fraudulent practices beyond price inflation—including misuse of the federal 340B drug discount program and overbilling for insulin pen needles.

Their lawsuit alleged that Walgreens engaged in:

🔹 Improper 340B Drug Dispensing – Walgreens allegedly diverted discounted 340B drugs meant for low-income patients and dispensed them to ineligible customers, all while failing to bill partner hospitals—Beth Israel Deaconess Medical Center, Tufts Medical Center, and Boston Medical Center—for the drugs.

🔹 Overbilling for Insulin Pen Needles – The company submitted excessive reimbursement claims for insulin needles, exploiting billing loopholes that led Medicaid and insurers to pay for more needles than patients actually needed.

🔹 Automatic 90-Day Prescription Switching – Walgreens converted patients’ prescriptions to 90-day supplies without medical justification, a practice that allegedly inflated costs for government healthcare programs.

The whistleblowers claim Walgreens had detailed internal records proving these practices were widespread.

Government Prosecutors and Legal Defense

Federal and state authorities pursued the case aggressively, with representatives from multiple attorney general offices involved in the legal battle.

🔹 For the Government:

• Steven Sharobem – U.S. Attorney’s Office for Massachusetts

• Ian Marinoff – Massachusetts Attorney General’s Office

• Richard Tangum – Georgia Attorney General’s Office

• Heather D'Orazio – Illinois Attorney General’s Office

🔹 For Walgreens:

• Peter Wilson – In-house counsel

• Selina Coleman – Reed Smith LLP

A Growing Legal Storm for Walgreens?

While this $2.8 million settlement resolves part of the lawsuit, the whistleblower claims suggest broader systemic fraud issues that could lead to further state and federal investigations.

With pharmaceutical pricing under national scrutiny, this case serves as a cautionary tale for major healthcare retailers navigating government reimbursements and compliance mandates.

As whistleblower-driven lawsuits continue to expose potential corporate misconduct in the healthcare sector, this Walgreens case could be just the tip of the iceberg.